Vol 24, No 4 (2020)
Original paper
Published online: 2020-11-12

open access

Page views 862
Article views/downloads 811
Get Citation

Connect on Social Media

Connect on Social Media

Association between hypertension and insulin resistance in non-diabetic adult populations: a community-based study from the Iran

Fatemeh Samiee Rad1, Sonia Oveisi1, Hamid Reza Javadi1, Ameneh Barikani1, Mohammad Sofiabadi2
Arterial Hypertension 2020;24(4):159-166.


Background and objectives: High blood pressure increases the probability of insulin resistance and hyperinsulinemia. Also, insulin resistance can be defined as a risk factor for hypertension. The present study investigated the relationship between hypertension and insulin resistance in non-diabetic participants who were referred to Qazvin Metabolic Diseases Center.

Material and methods: In this cross sectional study, 1103 participants (111 non-diabetic with newly diagnosed hypertension and 992 normotensive subjects aged ≥ 20 years) were enrolled from September 2014 to April 2016 in Qazvin (Iran). Systolic and diastolic blood pressure, insulin resistance, waist circumference, body mass index, triglycerides, cholesterol, LDL-cholesterol, fasting blood glucose (FBG) were measured. Fasting triglyceride to highdensity lipoprotein cholesterol ratio (TG/HDL-C) was used as a surrogate of insulin resistance. Data were analyzed using SPSS software and p < 0.05 was assumed as significant level.

Results: Ten percent of all participants had hypertension. TG/HDL-C was 3.78 ± 3.28 in non-HTN and 5.76 ± 5.35 in HTN participants (p < 0.001). The frequency of all cardio-metabolic risk factors (except HDL cholesterol level) was higher in hypertensive group, after adjusting for age and gender (p < 0.001).

Conclusion: Based on these results, essential hypertension is associated with a higher prevalence of hyperinsulinemia and insulin resistance in the non-diabetic community in Iran.

Article available in PDF format

View PDF Download PDF file


  1. GBD 2017 Risk Factor Collaborators, GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1345–1422.
  2. Patel P, Ordunez P, DiPette D, et al. [Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project]. J Clin Hyperten. 2016; 18(12): 1284–1294.
  3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017; 135(10): e146–e603.
  4. Rodgers A, Ezzati M, Vander Hoorn S, et al. Comparative Risk Assessment Collaborating Group, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360(9343): 1347–1360.
  5. Gaciong Z, Siński M, Lewandowski J. Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep. 2013; 15(6): 559–574.
  6. Chockalingam A. Impact of World Hypertension Day. Can J Cardiol. 2007; 23(7): 517–519.
  7. Lastra G, Syed S, Kurukulasuriya LR, et al. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014; 43(1): 103–122.
  8. Harati H, Hadaegh F, Saadat N, et al. Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC Public Health. 2009; 9: 186.
  9. Naruse M, Koike Y, Kamei N, et al. Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. PLoS One. 2019; 14(4): e0214727.
  10. Zhou MS, Schulman I. Link between Insulin Resistance and Hypertension: What Have We Learned from Our Ancestors? J Autacoids. 2012; 1–e102.
  11. Agata J, Miyazaki Y, Takada M, et al. Association of insulin resistance and hyperinsulinemia with disturbed lipid metabolism in patients with essential hypertension. Hypertens Res. 1998; 21(1): 57–62.
  12. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017; 23(7): 804–814.
  13. Sowers JR. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis. J Clin Pharmacol. 1992; 32(6): 529–535.
  14. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013; 3(1): 1–58.
  15. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5): 575–584.
  16. El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep. 2004; 6(3): 215–223.
  17. Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009; 33(2): 318–324.
  18. Fazizi F, Esmaillzadeh A, Mirmiran FP. Obesity and cardiovascular disease risk factors in Tehran adults: a population-based study. East Mediterr Health J. 2004; 10(6): 887–897.
  19. Bahrami H, Sadatsafavi M, Pourshams A, et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health. 2006; 6: 158.
  20. Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009; 33(2): 318–324.
  21. Salazar MR, Carbajal HA, Espeche WG, et al. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab Vasc Dis Res. 2013; 10(4): 346–352.
  22. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007; 356(3): 213–215.
  23. Abebe SM, Berhane Y, Worku A, et al. Diabetes mellitus in North West Ethiopia: a community based study. BMC Public Health. 2014; 14: 97.
  24. Yazdanpanah L, Shahbazian H, Shahbazian H. Prevalence, awareness and risk factors of hypertension in southwest of Iran. J Renal Inj Prev. 2015; 4(2): 51–56.
  25. Oori MJ, Mohammadi F, Norozi K, et al. Prevalence of HTN in Iran: Meta-analysis of Published Studies in 2004-2018. Curr Hypertens Rev. 2019; 15(2): 113–122.
  26. Eghbali M, Khosravi A, Feizi A, et al. Prevalence, awareness, treatment, control, and risk factors of hypertension among adults: a cross-sectional study in Iran. Epidemiol Health. 2018; 40: e2018020.
  27. World Health Organization. World Health Day 2013: measure your blood pressure, reduce your risk. www.who.int/ mediacentre/ news/ releases/2013/world_health_day_20130403/en/ (2018 Jun 4).
  28. Robitaille C, Dai S, Waters C, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. CMAJ. 2012; 184(1): E49–E56.
  29. Lloyd-Jones D, Adams R, Carnethon M. Epidemiology of hypertension. In: Bakris GL, Sorrentino MJ. ed. Hypertension: A Comanion to Braunwald’s Heart Disease. 2nd Ed Elsevier Inc 2012: 488.
  30. Zhou MS, Schulman IH, Zeng Q. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med. 2012; 17(5): 330–341.
  31. Cheung BMY, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012; 14(2): 160–166.
  32. Sinha S, Akhter Q, Banik S, et al. Correlation Study of Insulin Resistance and Essential Hypertension among Bangladeshi Male Volunteers. J Young Pharmac. 2015; 7(3): 200–205.
  33. Mulè G, Calcaterra I, Nardi E, et al. Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol. 2014; 6(9): 890–907.
  34. Rafieian-Kopaei M, Setorki M, Doudi M, et al. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014; 5(8): 927–946.
  35. Kim HK, Kim CH, Kim EH, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care. 2013; 36(2): 328–335.
  36. Kong YW, Baqar S, Jerums G, et al. Sodium and Its Role in Cardiovascular Disease - The Debate Continues. Front Endocrinol (Lausanne). 2016; 7: 164.
  37. Alcalá M, Sánchez-Vera I, Sevillano J, et al. Vitamin E reduces adipose tissue fibrosis, inflammation, and oxidative stress and improves metabolic profile in obesity. Obesity (Silver Spring). 2015; 23(8): 1598–1606.
  38. Janus A, Szahidewicz-Krupska E, Mazur G, et al. Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders. Mediators Inflamm. 2016; 2016: 3634948.
  39. Longo M, Zatterale F, Naderi J, et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019; 20(9).
  40. Orlando A, Viazzi F, Giussani M, et al. Endothelin-1/nitric oxide balance and HOMA index in children with excess weight and hypertension: a pathophysiological model of hypertension. Hypertens Res. 2019; 42(8): 1192–1199.